Astrazeneca
🤖
AI Overview
With $1.8M in lobbying spend across 29 quarterly filings, Astrazeneca is a significant lobbying presence.
$1.8M
Total Lobbying Spend
29
Quarterly Filings
1
Lobbying Firms Used
7
Individual Lobbyists
Spending by Year
| Year | Lobbying Spend |
|---|---|
| 2018 | $200K |
| 2019 | $100K |
| 2020 | $240K |
| 2021 | $240K |
| 2022 | $240K |
| 2023 | $240K |
| 2024 | $180K |
| 2025 | $360K |
Lobbying Firms
TIBER CREEK GROUP
What They Lobby For
- S. 469 Affordable and Safe Prescription Drug Importation Act, H.R. 1245 Affordable and Safe Prescription Drug Importation Act, issues related to pharmaceutical pricing and transparency. Issues regarding asthma/severe asthma/Family Asthma Act. Issues relating to 340b pricing.
- Issues relating to pharmaceutical pricing and transparency, HR 2550 Medicare Telehealth Parity Act of 2017. P.L. 115-123 - Bipartisan Budget Act of 2018, provisions relating to Part D coverage Gap.
- Issues related to pharmaceutical pricing and transparency. Issues relating to 340b pricing.
- Issues relating to Medicare Part D coverage Gap.
- Issues related to pharmaceutical pricing and transparency.
- Issues relating to Medicare Part D coverage gap. Issues relating to Part B pricing reform.
- Issues relating to Medicare Part D Pricing Reform. Issues relating to Medicare Part B pricing reform. Issues related to promoting value based arrangements in Medicare. Proposal to eliminate Medicaid inflationary cap. S.474 - SPIKE Act of 2019 S. 476 - C-Thru Act of 2019 S.475 -Rx Cap Act of 2019 S.62 - Empowering Medicare Seniors to Negotiate Drug Prices Act of 2019
- Issues related to pharmaceutical pricing and transparency. S. 2543 - The Prescription Drug Price Reduction Act. H.R.3 - Lower Drug Costs Now Act of 2019.
- Issues relating to Medicare Part D Pricing Reform. Issues relating to Medicare Part B pricing reform. Issues related to promoting value based arrangements in Medicare. Proposal to eliminate Medicaid inflationary cap. S. 2543 - The Prescription Drug Price Reduction Act. H.R.3 - Lower Drug Costs Now Act of 2019.
- Issues related to pharmaceutical pricing and transparency. S. 2543 - The Prescription Drug Price Reduction Act. H.R.3 - Lower Drug Costs Now Act of 2019. HR 6201 Families First Coronavirus Response Act (PL 116-27); CARES Act - S. 3548 (PL 116-136) - drug pricing issues.
Related Investigations
Big Pharma's $452M Lobbying Machine
How pharmaceutical companies spend hundreds of millions to influence health policy.
The 2025 Tariff Panic
As tariffs return, lobbying on trade surges.
Big Tech's $150M Lobbying War
Tech giants battle over AI, antitrust, privacy, and trade.
Who's Lobbying to Shape AI Policy
The AI regulation fight is the biggest lobbying battle of the decade.
Foreign Governments Are Lobbying Congress
1,000+ foreign entities from 50+ countries lobby the US government.
Federal Lobbying Statistics 2025
The definitive stats — $15.2B total, industry breakdowns, and trends.
What Is Lobbying? A Complete Guide
How lobbying works, who does it, and why it matters.
Explore More
Data Sources: Senate LDA Filings
Last updated: February 2026
This site is an independent journalism project. Analysis and editorial content are not affiliated with or endorsed by any government agency.